Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.

Yao N, Liu J, Xue Q, Liu J

Open source

DOI
10.3389/fphar.2026.1901617
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1901617,
  title = {Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.},
  author = {Yao N and Liu J and Xue Q and Liu J},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1901617},
  url = {https://doi.org/10.3389/fphar.2026.1901617}
}

RIS

TY  - JOUR
TI  - Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.
AU  - Yao N
AU  - Liu J
AU  - Xue Q
AU  - Liu J
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1901617
UR  - https://doi.org/10.3389/fphar.2026.1901617
ER  - 

APA

N, Y., J, L., Q, X., & J, L. (2026). Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1901617

Source records